Worldwide Healthcare Trust (WWH) Buys Back 680,003 Shares at 358.26p, Treasury Total Reaches 241 Million

The 24 June 2026 Share Repurchase: What the Company Disclosed

Worldwide Healthcare Trust PLC confirmed on 24 June 2026 that it had completed a market purchase of 680,003 ordinary shares at a single price of 358.26 pence per share. The announcement was made pursuant to the authority granted to the board at a General Meeting of the company held on 2 June 2026, which permitted market purchases of the company's own shares up to an aggregate maximum of 54,510,546 ordinary shares. Each share carries a nominal value of 2.5 pence.

The total cash consideration implied by this single transaction — calculated from the 680,003 shares acquired at 358.26p — amounts to approximately £2.44 million, though the company did not explicitly state a total consideration figure in the announcement. Investors should note that this figure is derived directly from the disclosed share count and price and is offered here as a factual calculation rather than a separately confirmed disclosure. The announcement confirms the shares will be held in treasury rather than cancelled, preserving the potential for the company to reissue them at a later date should market conditions Warrant it.

Buyback Authority Granted at the 2 June 2026 General Meeting

The authority underpinning this repurchase was formally approved by shareholders at a General Meeting of Worldwide Healthcare Trust held on 2 June 2026. Under that mandate, the company is permitted to repurchase up to a maximum of 54,510,546 ordinary shares in the open market. Such authorities are standard practice for UK-listed investment trusts and are routinely sought as a tool to manage the discount at which the trust's shares may trade relative to its net asset value (NAV).

The disclosure does not state how many shares have been repurchased under this specific authority in total to date, nor does it confirm precisely how much of the 54,510,546-share limit has been consumed. Investors wishing to track remaining buyback headroom should monitor subsequent market notifications, which the company is obliged to publish each time a transaction in its own shares is executed. The frequency and scale of such notifications can provide a useful signal of how actively the board is deploying this tool.

Treasury Share Position Following the Transaction

Following the purchase of 680,003 shares on 24 June 2026, the total number of ordinary shares held by Worldwide Healthcare Trust in treasury stands at 241,356,426. Treasury shares are shares that have been bought back by a company but not cancelled; they sit on the Balance Sheet without carrying voting rights and can be reissued at a future date, for example to satisfy employee share schemes or at a premium to the buyback price if the discount narrows sufficiently.

The scale of the treasury holding — in excess of 241 million shares — is notable relative to the total issued Share Capital of 601,665,200 ordinary shares. This means that approximately 40 per cent of the company's total issued ordinary shares are currently held in treasury, a proportion that underlines the extent to which share Buybacks have been used as a capital management mechanism by the Worldwide Healthcare Trust board over time. The company did not disclose in this announcement the aggregate cost at which the treasury position was accumulated.

Total Voting Rights and the FCA Denominator Calculation

As a result of the transaction, the total number of voting rights in Worldwide Healthcare Trust following the repurchase is 360,308,774. This figure is calculated as the total shares in issue (601,665,200) less the shares held in treasury (241,356,426), since treasury shares do not carry voting rights under UK company law. The company has highlighted this figure explicitly in its announcement for a specific regulatory purpose.

Under the FCA's Disclosure Guidance and Transparency Rules (DTR), shareholders must monitor their percentage holding against the total number of voting rights in a company and notify the company — and subsequently the market — if their interest crosses certain prescribed thresholds. The announcement states that 360,308,774 is the denominator figure that shareholders should use for this calculation following the repurchase. Any Shareholder whose proportionate voting interest has moved across a notifiable threshold as a result of this transaction would be required to make the appropriate DTR disclosure. This is a routine but important compliance obligation for significant shareholders.

How WWH's Discount-Management Strategy Works in Practice

Worldwide Healthcare Trust is a specialist investment trust that invests primarily in global healthcare and pharmaceutical stocks. Like many closed-ended investment trusts listed on the London Stock Exchange, WWH's shares can trade at either a premium or a discount to the underlying net asset value of its portfolio. When shares trade at a discount — meaning investors can buy a pound of Assets for less than a pound — the board has the option to buy back shares in the open market, which can support the share price and reduce the discount.

By purchasing shares at a discount to NAV and holding them in treasury, the trust effectively increases the NAV per share for remaining shareholders, since the same pool of assets is now spread across a smaller number of shares with voting and economic rights. This mechanism is widely used across the UK investment trust sector and is considered a shareholder-friendly capital management tool. Whether the current buyback programme is materially closing any discount to NAV is a question investors will wish to track through the trust's regular NAV announcements and share price data, which the company did not address in this specific notification.

Frostrow Capital LLP's Role as Company Secretary

The announcement was made for and on behalf of Frostrow Capital LLP, which acts as Company Secretary to Worldwide Healthcare Trust PLC. Frostrow Capital is a well-established provider of company secretarial, administrative, and governance services to UK-listed investment trusts, and its name appearing on regulatory notifications of this nature is standard practice for the trusts it services. The contact for further information is given as Mark Pope at Frostrow Capital LLP, reachable on 020 3 008 4913.

The involvement of a specialist third-party administrator such as Frostrow Capital in the day-to-day secretarial and compliance functions of the trust is common in the investment trust industry, where the investment manager (responsible for portfolio decisions) and the administrative function are typically separate. Investors should note that the investment management of Worldwide Healthcare Trust's portfolio is a distinct function carried out separately from the secretarial role performed by Frostrow Capital.

Implications for the Remaining Share Buyback Programme Limit

The General Meeting held on 2 June 2026 authorised the repurchase of up to 54,510,546 ordinary shares in aggregate. The 680,003 shares purchased on 24 June 2026 represent approximately 1.25 per cent of that total authority. The announcement does not state what cumulative total has been purchased under this specific authority since it was granted on 2 June 2026, so the precise remaining headroom cannot be definitively stated from the information provided.

Investors monitoring WWH's buyback activity should note that such authority is typically valid for a defined period — usually until the next Annual General Meeting or a set calendar date — and that the board is under no obligation to deploy the full limit. The pace at which the authority is being used may reflect management's assessment of prevailing discount levels, market conditions, and available Liquidity. Market Participants who follow the trust closely will likely watch for further transaction-in-own-shares notifications to gauge the trajectory of the programme.

Context Within the Wider UK Investment Trust Buyback Landscape

Share buybacks have been a prominent feature of the UK investment trust sector in recent years, as many trusts have faced persistent discounts to NAV in a challenging macroeconomic environment marked by elevated interest rates and shifting investor risk appetite. Sector bodies and analysts have tracked aggregate buyback activity across the sector as a measure of boards' commitment to discount control, and the Volume of repurchases by individual trusts has attracted increasing scrutiny from investors and commentators.

Worldwide Healthcare Trust, with its focus on global healthcare equities, operates in a sector that has experienced considerable performance variation in recent years, reflecting factors including drug pricing policy developments, Patent cliffs for major pharmaceutical companies, and the evolving regulatory environment in the United States and Europe. The board's decision to maintain an active buyback programme amid this backdrop may be interpreted by some investors as a signal of confidence in the long-term value of the underlying portfolio, though the announcement itself makes no such forward-looking claims, and investors should conduct their own analysis before drawing conclusions.

What Shareholders and Prospective Investors Should Monitor Going Forward

For existing shareholders in Worldwide Healthcare Trust, the updated denominator of 360,308,774 voting rights is the most immediately actionable piece of information in this announcement, particularly for any investor whose holding may be close to a DTR notification threshold. Any shareholder uncertain about whether a threshold has been crossed as a result of this repurchase should seek appropriate regulatory or legal advice promptly.

More broadly, investors may wish to track the frequency and volume of future buyback notifications from WWH, the trust's published NAV per share figures, and the evolving premium or discount at which the shares trade in the Secondary Market. The immediate share price impact of this specific buyback was not clear from available public information. Updates to the trust's portfolio, performance data, and any further changes to its Capital Structure are expected to be disclosed through the Regulatory News Service in due course, and investors are encouraged to review all such announcements carefully.